MSBase oral and poster presentations for ECTRIMS 2017

Ilya Kister, New York University School of Medicine, United States - poster presentation:

Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis


Johannes Lorscheider, University Hospital of Basel, Switzerland - poster presentation:

Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis


Tomas Kalincik, University of Melbourne and Royal Melbourne Hospital, Australia

Poster presentations:

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study.

Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years.

Risk of secondary progressive multiple sclerosis: a longitudinal study. (Adam Fambiatos - MD student, University of Melbourne).

Contribution of inflammation to disability accrual in primary progressive multiple sclerosis. (Jordana Hughes - MD student, University of Melbourne).

Oral Presentation:

Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. (Bernd Merkel - University of Melbourne Postdoctoral Research Fellow)


William Brown, MSBase Research Fellow, Melbourne, Australia - oral presentation:

The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis


Yara Fragoso, Metropolitan University of Santos, Brazil - ePoster Presentation:

Halting disability progression in multiple sclerosis with immunomodulatory injectable treatments: is it achievable?


Tim Spelman, MSBase Statistician - poster presentations:

A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from the MSBase Registry in preparation for a cost effectiveness model: Patients switching within firstline agents or to Natalizumab or Fingolimod in active RRMS

Persistence to fingolimod compared with other disease modifying therapies in the Australian Real-World setting using the MSBase Registry


Vilija Jokubaitis, University of Melbourne, Australia - poster presentation:

Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis


Amy Kunchok, University of Melbourne, Australia - poster presentation:

Prognostic value of low level MRI activity in treated RRMS


Myintzu Min, John Hunter Hospital, Newcastle, Australia - poster presentation:

Silent lesions on MRI - shifting goal post for treatment decisions in MS